Glomerulonephritis Kidney TransplantNCT07783737
China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study
An observational study of Glomerulonephritis Kidney Transplant, run by AstraZeneca at 9 sites in China.
Trial summary
This is a prospective observational study aimed at establishing a prospective observational cohort of patients with a confirmed diagnosis of glomerulonephritis (GN) before kidney transplantation in China. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Glomerulonephritis Kidney Transplant
- How many people
- 300 participants
- Where
- 9 sitesChina
- Study dates
- 1 Oct 2026to 29 Aug 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients with a confirmed diagnosis of primary GN before kidney transplantation
Who may be able to join
- Age ≥ 18 years.
- Diagnosed with primary GN based on clinical guidelines and/or expert consensus
- Successfully matching completed and confirmed to be scheduled for kidney transplantation.
Who cannot join
- History of organ transplantation or planned multiple organ transplantation.
- Complicated with malignancy.
- Failure to undergo kidney transplantation for any reason.
- Unable to provide written informed consent form (ICF).
Trial locations and contacts
9 sites in 1 country. Contact the study team or a site near you to ask about taking part.
AstraZeneca Clinical Study Information Center contact
9 sites in 1 country
China9 sites, 8 recruiting
- Not yet recruiting
Research Site
Beijing, Beijing Municipality
- Not yet recruiting
Research Site
Guangzhou, Guangdong
- Recruiting
Research Site
Nanning, Guangxi
- Terminated
Research Site
Shanghai, Shanghai Municipality
- Not yet recruiting
Research Site
Taiyuan, Shanxi
- Not yet recruiting
Research Cite
Tianjin, Tianjin Municipality
- Not yet recruiting
Research Site
Wuhan, Hubei
- Not yet recruiting
Research Site
Yantai, Shandong
- Not yet recruiting
Research Site
Zhengzhou, Henan
About this study
This is a prospective observational study aimed at establishing a prospective observational cohort of patients with a confirmed diagnosis of glomerulonephritis (GN) before kidney transplantation in China. Information will be collected on the epidemiology of GN recurrence after kidney transplantation, as well as the outcomes and treatment of the primary disease following kidney transplantation, to provide evidence for subsequent clinical studies, drug development, and translational research.
Approximately 300 patients with a confirmed diagnosis of GN before transplantation will be prospectively enrolled. Clinical data will be collected during screening, kidney transplantation, and a 3-year post-transplant follow-up. The frequency of follow-up visits is every 3 months in the 1st year after transplantation, and every 6 months during the 2nd to 3rd years, with a total of 8 follow-up visits. The study will be conducted at 10 sites across China.
- Conditions
- Glomerulonephritis Kidney Transplant
- Keywords
- glomerulonephritis, GN
- Medical subject headings
- Glomerulonephritis
What is being measured
The primary outcome is the main question the study is designed to answer.
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Incidence of GN recurrence after kidney transplantation
Measured: 3-year follow-up
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Time to GN recurrence after kidney transplantation (months)
Measured: 3-year follow-up
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Factors associated with GN recurrence after kidney transplantation
Measured: 3-year follow-up
Secondary outcomes (3)
To assess other clinical events after kidney transplantation and their associated factors
incidence and time to rejection
Measured: 3-year follow-up
To assess other clinical events after kidney transplantation and their associated factors
incidence and time to renal allograft loss
Measured: 3-year follow-up
To assess other clinical events after kidney transplantation and their associated factors
incidence and time to death
Measured: 3-year follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Aug 2026
- Study start1 Oct 2026
- Primary completion29 Aug 2030 (estimated)
- Study completion29 Aug 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Glomerulonephritis Kidney TransplantStudies of the same condition, open and under way.
- More trials run by AstraZenecaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AstraZeneca
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07783737
- Sponsor's protocol ID
- D9030R00002
- Status last verified
- Oct 2026
- First submitted
- 21 Aug 2026
- Last updated
- 21 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Study at a glance
From the registry record, last updated by the sponsor on 21 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- China Glomerulonephritis Kidney Transplant Recipient Cohort: A Prospective Multicenter Observational Study
- ClinicalTrials.gov ID
- NCT07783737
- Acronym / sponsor ID
- D9030R00002
- Conditions
- Glomerulonephritis Kidney Transplant
- Keywords
- glomerulonephritis, GN
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- AstraZenecaIndustry (pharma, biotech, devices)
- Study start
- 1 Oct 2026 (actual)
- Primary completion
- 29 Aug 2030 (estimated)
- Study completion
- 29 Aug 2030 (estimated)
- First posted
- 25 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a prospective observational study aimed at establishing a prospective observational cohort of patients with a confirmed diagnosis of glomerulonephritis (GN) before kidney transplantation in China. Information will be collected on the epidemiology of GN recurrence after kidney transplantation, as well as the outcomes and treatment of the primary disease following kidney transplantation, to provide evidence for subsequent clinical studies, drug development, and translational research.
Approximately 300 patients with a confirmed diagnosis of GN before transplantation will be prospectively enrolled. Clinical data will be collected during screening, kidney transplantation, and a 3-year post-transplant follow-up. The frequency of follow-up visits is every 3 months in the 1st year after transplantation, and every 6 months during the 2nd to 3rd years, with a total of 8 follow-up visits. The study will be conducted at 10 sites across China.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients with a confirmed diagnosis of primary GN before kidney transplantation
Key inclusion criteria (3 listed)
- Age ≥ 18 years.
- Diagnosed with primary GN based on clinical guidelines and/or expert consensus
- Successfully matching completed and confirmed to be scheduled for kidney transplantation.
Key exclusion criteria (4 listed)
- History of organ transplantation or planned multiple organ transplantation.
- Complicated with malignancy.
- Failure to undergo kidney transplantation for any reason.
- Unable to provide written informed consent form (ICF).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Time frame: 3-year follow-up
Incidence of GN recurrence after kidney transplantation
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Time frame: 3-year follow-up
Time to GN recurrence after kidney transplantation (months)
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors
Time frame: 3-year follow-up
Factors associated with GN recurrence after kidney transplantation
3 secondary outcomes
To assess other clinical events after kidney transplantation and their associated factors
Time frame: 3-year follow-up
To assess other clinical events after kidney transplantation and their associated factors
Time frame: 3-year follow-up
To assess other clinical events after kidney transplantation and their associated factors
Time frame: 3-year follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Oct 2026.
- Individual participant dataSharing planned: Yes. Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Related trials for Glomerulonephritis Kidney Transplant
Not yet recruitingPhase 3
A Study to Assess the Efficacy and Safety of Pegcetacoplan for the Prevention of Recurrent C3G or Primary IC-MPGN in Kidney Transplant Recipients
C3 Glomerulopathy (C3G), Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Recurrent Glomerular Disease After Kidney Transplantation
Not yet recruiting
MYTP01 for Immune-Mediated Diseases
IgA Nephropathy, Kidney Transplant Recipients
RecruitingPhase 1/2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
Autoimmune Disorders, Systemic Sclerosis
Recruiting
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
Focal Segmental Glomerulosclerosis
Recruiting
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
Focal Segmental Glomerulosclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
AstraZeneca Clinical Study Information Center contact
9 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Glomerulonephritis Kidney Transplant, run by AstraZeneca at 9 sites in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 21 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 9 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact AstraZeneca Clinical Study Information Center (1-877-240-9479, information.center@astrazeneca.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To assess the incidence of GN recurrence after kidney transplantation and its influencing factors (time frame: 3-year follow-up). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2026.